JP2002507566A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002507566A5 JP2002507566A5 JP2000537542A JP2000537542A JP2002507566A5 JP 2002507566 A5 JP2002507566 A5 JP 2002507566A5 JP 2000537542 A JP2000537542 A JP 2000537542A JP 2000537542 A JP2000537542 A JP 2000537542A JP 2002507566 A5 JP2002507566 A5 JP 2002507566A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- oxybutynin
- release dosage
- weight
- incontinence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002552 dosage form Substances 0.000 claims description 33
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 claims description 18
- 229960005434 oxybutynin Drugs 0.000 claims description 17
- 238000013268 sustained release Methods 0.000 claims description 13
- 239000012730 sustained-release form Substances 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 12
- 208000005946 Xerostomia Diseases 0.000 claims description 11
- 206010013781 dry mouth Diseases 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 8
- 230000001629 suppression Effects 0.000 claims description 2
- 238000010276 construction Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 15
- 206010021639 Incontinence Diseases 0.000 description 11
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 11
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 206010046543 Urinary incontinence Diseases 0.000 description 6
- 239000012530 fluid Substances 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 4
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 4
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 4
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 4
- 239000008240 homogeneous mixture Substances 0.000 description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 230000003204 osmotic effect Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000017 hydrogel Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 231100001274 therapeutic index Toxicity 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 208000008967 Enuresis Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 description 1
- 206010029279 Neurogenic bladder Diseases 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- -1 hydroxypropyl Chemical group 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 231100000324 minimal toxicity Toxicity 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 208000005346 nocturnal enuresis Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7942998P | 1998-03-26 | 1998-03-26 | |
| US60/079,429 | 1998-03-26 | ||
| PCT/US1999/006049 WO1999048494A1 (en) | 1998-03-26 | 1999-03-19 | Sustained-release composition of oxybutynin with reduced xerostomia effect |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002507566A JP2002507566A (ja) | 2002-03-12 |
| JP2002507566A5 true JP2002507566A5 (enExample) | 2005-06-02 |
Family
ID=22150487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000537542A Pending JP2002507566A (ja) | 1998-03-26 | 1999-03-19 | 口内乾燥症を低減させるオキシブチニン徐放性組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20010009995A1 (enExample) |
| JP (1) | JP2002507566A (enExample) |
| AR (1) | AR018321A1 (enExample) |
| AU (1) | AU3103799A (enExample) |
| WO (1) | WO1999048494A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6403600A (en) * | 1999-06-10 | 2001-01-02 | Sepracor, Inc. | Methods and compositions for treating urinary frequency and urgency using optically pure (s)-oxybutynin |
| US7179483B2 (en) | 2000-04-26 | 2007-02-20 | Watson Pharmaceuticals, Inc. | Compositions and methods for transdermal oxybutynin therapy |
| CN1438861A (zh) | 2000-04-26 | 2003-08-27 | 沃特森药物公司 | 最小化与奥昔布宁疗法有关的副作用 |
| US7029694B2 (en) | 2000-04-26 | 2006-04-18 | Watson Laboratories, Inc. | Compositions and methods for transdermal oxybutynin therapy |
| AR053986A1 (es) | 2004-12-03 | 2007-05-30 | Osmotica Pharmaceutical Argent | Dispositivo osmotico que contiene amantadina y una sal osmotica |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2799241A (en) * | 1949-01-21 | 1957-07-16 | Wisconsin Alumni Res Found | Means for applying coatings to tablets or the like |
| US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| GB1478759A (en) * | 1974-11-18 | 1977-07-06 | Alza Corp | Process for forming outlet passageways in pills using a laser |
| US4008719A (en) * | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4063064A (en) * | 1976-02-23 | 1977-12-13 | Coherent Radiation | Apparatus for tracking moving workpiece by a laser beam |
| US4285987A (en) * | 1978-10-23 | 1981-08-25 | Alza Corporation | Process for manufacturing device with dispersion zone |
| US4200098A (en) * | 1978-10-23 | 1980-04-29 | Alza Corporation | Osmotic system with distribution zone for dispensing beneficial agent |
| US4327725A (en) * | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
| US4783337A (en) * | 1983-05-11 | 1988-11-08 | Alza Corporation | Osmotic system comprising plurality of members for dispensing drug |
| US4612008A (en) * | 1983-05-11 | 1986-09-16 | Alza Corporation | Osmotic device with dual thermodynamic activity |
| US4863456A (en) * | 1986-04-30 | 1989-09-05 | Alza Corporation | Dosage form with improved delivery capability |
| US4816263A (en) * | 1987-10-02 | 1989-03-28 | Alza Corporation | Dosage form for treating cardiovascular diseases comprising isradipine |
| US4902514A (en) * | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| US5178868A (en) * | 1988-10-26 | 1993-01-12 | Kabi Pharmacia Aktiebolaq | Dosage form |
| US5202128A (en) * | 1989-01-06 | 1993-04-13 | F. H. Faulding & Co. Limited | Sustained release pharmaceutical composition |
| SE8904296D0 (sv) * | 1989-12-21 | 1989-12-21 | Pharmacia Ab | Transdermal system |
| US5480651A (en) * | 1992-03-16 | 1996-01-02 | Regents Of The University Of California | Composition and method for treating nicotine craving in smoking cessation |
| JP2665858B2 (ja) * | 1992-05-30 | 1997-10-22 | 日本ヘキスト・マリオン・ルセル株式会社 | 持効性塩酸オキシブチニン製剤 |
| US5399359A (en) * | 1994-03-04 | 1995-03-21 | Edward Mendell Co., Inc. | Controlled release oxybutynin formulations |
| WO1996012477A1 (en) * | 1994-10-21 | 1996-05-02 | Leiras Oy | Controlled release oral delivery system containing oxybutynin |
| US5965161A (en) * | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
| US5532278A (en) * | 1995-01-31 | 1996-07-02 | Sepracor, Inc. | Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin |
| US6262115B1 (en) * | 1995-05-22 | 2001-07-17 | Alza Coporation | Method for the management of incontinence |
| US5912268A (en) * | 1995-05-22 | 1999-06-15 | Alza Corporation | Dosage form and method for treating incontinence |
| US5674895A (en) * | 1995-05-22 | 1997-10-07 | Alza Corporation | Dosage form comprising oxybutynin |
| ATE214229T1 (de) * | 1996-04-11 | 2002-03-15 | Basf Ag | Fungizide mischungen |
| WO1998043555A1 (en) * | 1997-04-03 | 1998-10-08 | Point Biomedical Corporation | Intravesical drug delivery system |
| CN1438861A (zh) * | 2000-04-26 | 2003-08-27 | 沃特森药物公司 | 最小化与奥昔布宁疗法有关的副作用 |
| US6368628B1 (en) * | 2000-05-26 | 2002-04-09 | Pharma Pass Llc | Sustained release pharmaceutical composition free of food effect |
| US20030185882A1 (en) * | 2001-11-06 | 2003-10-02 | Vergez Juan A. | Pharmaceutical compositions containing oxybutynin |
-
1999
- 1999-03-05 AR ARP990100963A patent/AR018321A1/es unknown
- 1999-03-19 JP JP2000537542A patent/JP2002507566A/ja active Pending
- 1999-03-19 WO PCT/US1999/006049 patent/WO1999048494A1/en not_active Ceased
- 1999-03-19 AU AU31037/99A patent/AU3103799A/en not_active Abandoned
-
2001
- 2001-03-07 US US09/801,443 patent/US20010009995A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101287457B (zh) | Treprostinil用于治疗神经性糖尿病的足部溃疡的用途 | |
| CN1440283A (zh) | 有机化合物的联合形式 | |
| CN1400903A (zh) | 用于治疗鼻炎/结膜炎的非镇静抗组胺药物与影响白三烯活性物质的新药物并用 | |
| JP2001172181A (ja) | 経口投与後のトリメタジジンの持続性放出を可能とするマトリックス錠 | |
| TW200831078A (en) | Angiotensin II receptor antagonist for the prevention or treatment of systemic diseases in cats | |
| JP2003519228A5 (enExample) | ||
| RU2308268C2 (ru) | Производные арил- или гетероарилазолилкарбинолов для лечения недержания мочи | |
| JPH10158169A (ja) | 塩化トロスピウムを含んだ医薬製剤、その調整方法および使用方法 | |
| JP2004143175A (ja) | 薬物の経口投与用徐放性組成物 | |
| CN113546089B (zh) | 1-乙基-3，7-二甲基黄嘌呤在制备治疗肺炎药物中的应用 | |
| JP2002507566A5 (enExample) | ||
| JP2013199506A (ja) | 処置方法 | |
| WO2008101375A1 (en) | A gastric retentive sustained-release pharmaceutical composition comprising irbesartan | |
| CN101485659A (zh) | 氨氯地平与辛伐他汀的药用组合物及其制备方法与应用 | |
| CN101057861B (zh) | 一种聚卡波菲肠溶药物组合物 | |
| CN102485228B (zh) | 一种药物组合物及其用途 | |
| JPWO2016121147A1 (ja) | 注腸剤 | |
| CN102397278A (zh) | 一种抗高血压药物组合物 | |
| JP4702054B2 (ja) | 増強剤 | |
| CN104324377A (zh) | 一种复方降压制剂及其应用 | |
| JP2000119186A (ja) | スクラルファート含有局所投与用医薬組成物 | |
| CN100518737C (zh) | 一种西洛他唑固体制剂 | |
| KR20070074576A (ko) | 사구체 질환 치료제 | |
| CN113546083B (zh) | 治疗肺炎的药物组合物 | |
| JPH04134030A (ja) | 徐放性モルヒネ直腸投与製剤 |